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Objectives The aim of this study was to evaluate the efficacy of drug-eluting balloons (DEB) compared with paclitaxel-
eluting stents (PES) for the reduction of restenosis in small vessels.
Background DEB have been shown to be effective in the treatment of coronary in-stent restenosis, but data are limited re-
garding their efficacy in de novo disease.
Methods BELLO (Balloon Elution and Late Loss Optimization) is a prospective, multicenter trial that randomized 182 pa-
tients with lesions located in small vessels (reference diameter 2.8 mm) to treatment with paclitaxel DEB and
provisional bare-metal stenting (n  90) or PES implantation (n  92). The primary endpoint was noninferiority
of angiographic in-stent (in-balloon) late loss with a delta of 0.25 mm. Secondary endpoints were angiographic
restenosis, target lesion revascularization, and major adverse cardiac events (MACE; death, myocardial infarc-
tion, target vessel revascularization) at 6 months.
Results Baseline characteristics were well matched, except for a smaller vessel size in the DEB group (2.15  0.27 mm
vs. 2.25  0.24 mm; p  0.003). The majority (89%) of lesions involved vessels with a diameter 2.5 mm. Bail-
out stenting was required in 20% of lesions in the DEB group. The primary endpoint of in-stent (in-balloon) late
loss was significantly less with DEB compared with PES (0.08  0.38 mm vs. 0.29  0.44 mm; difference
0.21; 95% CI: 0.34 to 0.09; pnoninferiority  0.001; psuperiority  0.001). At 6 months, DEB and PES were as-
sociated with similar rates of angiographic restenosis (8.9% vs. 14.1%; p  0.25), target lesion revascular-
ization (4.4% vs. 7.6%; p  0.37), and MACE (7.8% vs. 13.2%; p  0.77).
Conclusions Treatment of small-vessel disease with a paclitaxel DEB was associated with less angiographic late loss and similar
rates of restenosis and revascularization as a PES. (Balloon Elution and Late Loss Optimization [BELLO]; Study
NCT01086579) (J Am Coll Cardiol 2012;60:2473–80) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.020Drug-eluting balloons (DEB) are emerging as an effective
treatment for in-stent restenosis in both bare-metal stents
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sels remain a lesion subset in
which DES remain associated
with relatively high restenosis
rates, especially in real-world pa-
tients and registries (5,6). In
some circumstances, the extent of
the disease may demand implanta-
tion of long stents. Therefore, a
suitable alternative to stent im-
plantation to treat small-vessel dis-
ease is desirable. In addition, treat-
ment of patients with multivessel
disease could benefit from a strat-
egy of DES implantation on the
proximal major epicardial vessels
and angioplasty with DEB of
more distal lesions. DEB may also
provide significant theoretical ad-
vantages over DES such as a lower
risk of stent thrombosis, shorter
durations, and less dependence on
dual antiplatelet therapy.
Because limited and inconsistent data are available for
DEB in small-vessel disease (7,8), we performed a random-
ized study to evaluate the efficacy and safety of DEB as
compared with paclitaxel-eluting stent (PES) implantation
for the reduction of restenosis in patients with coronary
artery disease in small vessels.
Methods
The BELLO (Balloon Elution and Late Loss Optimiza-
tion) trial was an investigator-initiated, prospective, multi-
center, single-blinded, active-treatment controlled clinical
trial in which 182 patients undergoing percutaneous revascu-
larization of small coronary vessels (reference vessel diameter
[RVD] 2.8 mm by visual estimation) were randomly as-
signed in a 1:1 ratio to treatment with: 1) IN.PACT Falcon
paclitaxel DEB (Medtronic, Inc., Santa Rosa, California)
dilation and provisional BMS; or 2) PES (Taxus Libertè,
Boston Scientific, Boston, Massachusetts) implantation as
per standard practice. Eligible patients were age 18 years or
older, with a diagnosis of stable or unstable angina or
documented silent ischemia and a maximum of 2 angio-
graphically significant de novo target lesions 25 mm in
length in native coronary arteries with a visually estimated
RVD 2.8 mm. Clinical exclusion criteria included acute
myocardial infarction (MI) within the previous 48 h; pre-
vious percutaneous coronary intervention within the last 3
months; elective surgery planned within 6 months after the
procedure; left ventricular ejection fraction 30%; serum
creatinine 2.0 mol/l; contraindication or suspected in-
tolerance to paclitaxel, aspirin, thienopyridines, or iodinated
contrast that cannot be pre-treated; platelet count 50,000
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DEB  drug-eluting
balloon(s)
DES  drug-eluting stent(s)
ECG  electrocardiogram
MACE  major adverse
cardiac event
MI  myocardial infarction
MLD  minimum lumen
diameter
PES  paclitaxel-eluting
stents
RVD  reference vessel
diameter
TLR  target lesion
revascularization
TVR  target vessel
revascularizationcells/mm; positive pregnancy test; and stroke within theprevious 6 months. Angiographic exclusion criteria were
more than 3 epicardial vessels requiring revascularization,
aorto-ostial lesions, restenotic lesions, lesions in bypass
grafts, chronic total occlusions, thrombus within the target
lesion, and bifurcation lesions in which the operator decides
that a 2-stent technique as intention to treat is required or
bifurcations with side branches 2.5 mm. Treatment of
other lesions not meeting the inclusion criteria (i.e., non-
target lesions located in large vessels) during the index
procedure was permitted, but the lesion must have been
successfully treated before randomization and not with the
study device (DEB).
The study protocol was approved by the ethics commit-
tees at each participating center, and all patients provided
written informed consent.
Procedure. After successfully treatment of nontarget le-
sions and crossing of the target lesion with a guidewire,
patients were randomized to the treatment arms with the
use of sealed opaque envelopes containing a computer-
generated randomization sequence. In the case of treatment
of more than 1 target lesion, the treatment selected had to
remain the same for both lesions. In the DEB arm,
pre-dilation with a standard balloon was recommended in
all lesions. The diameter and length of the DEB were
selected with a balloon:artery ratio of 1:1 and 2.5 to 5 mm
(per edge) longer, respectively, than the target lesion.
DEB were inflated only once for 30 to 60 s at an inflation
pressure approximately or slightly beyond nominal to
achieve complete apposition of the balloon on the vessel
wall, while trying to avoid edge dissection. Bailout
provisional stenting with BMS was permitted in the
DEB arm only in cases of a suboptimal result, defined as
a persistent residual stenosis refractory to optimal balloon
dilation or in cases of flow-limiting dissection. In cases of
stenting, the protocol recommended using the shortest
stent length to fully cover the residual stenosis or seal the
dissection and recommended that the stent be deployed
entirely within the area treated with DEB to avoid
geographic miss. In the PES arm, stent implantation was
performed as per standard practice and post-dilation per
operator’s discretion.
All patients were pre-treated with aspirin and either
ticlopidine or clopidogrel. A 600-mg loading dose of clopi-
dogrel before the index procedure was administered if
patients were not pre-treated. Procedural anticoagulation
was achieved with either intravenous unfractionated heparin
or bivalirudin per standard of care, and the administration of
glycoprotein IIb/IIIa inhibitors was per operator’s discre-
tion. Following the procedure, an electrocardiogram (ECG)
was performed and cardiac enzyme levels were measured.
The protocol recommended that patients receive aspirin
indefinitely and daily clopidogrel (or ticlopidine, if required)
for a minimum of: 1) 30 days in case of treatment with only
DEB; 2) 3 months in case of provisional BMS after DEB;
and 3) 12 months after DES implantation. Clinical
follow-up was performed with visits or telephone contact at
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the entire study period. Protocol-specified angiographic
follow-up was scheduled at 6 months after the procedure for
all patients unless necessary at an earlier time for clinical
reasons.
Quantitative coronary angiographic measurements. Coro-
nary angiograms were analyzed offline using a validated edge
detection system (CMS, version 5.2, Medis Medical Imag-
ing Systems BV, Leiden, the Netherlands) by an expert
operator at an independent core laboratory (Mediolanum
Cardio Research, Milan, Italy). Minimal lumen diameter
(MLD), RVD, and percent diameter stenosis were mea-
sured at baseline, post-procedure, and follow-up. All angio-
graphic parameters were calculated both in-stent and in-
segment (stent and 5 mm proximal and distal). In the DEB
group, in-stent referred to the in-balloon measurement
(irrespective of whether bailout BMS implantation was
performed), whereas in-segment was defined as the segment
treated with the DEB, including 5 mm proximal and distal.
For accurate performance of these analyses for the DEB
group, the protocol mandated that the operator film the
inflated DEB and that the final and follow-up angiogram be
performed in the same projection. Late lumen loss was
defined as the difference between the MLD immediately
after the procedure and at 6-month follow-up. Net lumen
gain was defined as the difference between the MLD at
follow-up and at baseline. Binary angiographic restenosis
was defined as diameter stenosis 50% by quantitative
coronary angiography within a previously stented segment
(stent and 5 mm proximal and distal) at the follow-up
angiogram. The pattern of restenosis at follow-up was
categorized according to the Mehran classification (9).
Study endpoints and definitions. The primary endpoint
of the study was angiographic in-stent (in-balloon) late
lumen loss at follow-up angiography. Secondary endpoints
included the occurrence of major adverse cardiac events
(MACE), defined as the composite of death, Q- or non–Q-
wave MI, or target vessel revascularization (TVR) at 30 days
and 6 months. Additional prespecified secondary endpoints
included target lesion revascularization (TLR), binary reste-
nosis, device success, and procedural success. TVR was
defined as any repeat revascularization of the target vessel,
and TLR was defined as any repeat revascularization within
the stented or DEB-treated segment. Periprocedural MI
was defined as an elevation of cardiac biomarkers (troponin
or creatine kinase-myocardial band) 3 times the upper
limit of normal. Nonprocedural acute MI was defined as an
elevation of troponin above the upper range limit in com-
bination with at least one of the following: ischemic
symptoms, ECG changes indicative of new ischemia, de-
velopment of new pathological Q waves on ECG, or
imaging evidence of new loss of viable myocardium or new
regional wall motion abnormality (10). Stent thrombosis
was classified according to the Academic Research Consor-
tium definition (11). Device success was defined as the
ability of the investigational device to be delivered, dilated,and retrieved from the target lesion. Procedural success was
defined as device success without the occurrence of death,
MI, or repeat revascularization of the target lesion during
the hospital stay. Independent study monitors verified data
from case report forms on-site. The clinical study endpoints
were adjudicated by an independent clinical events commit-
tee, blinded to treatment allocation, after review of original
source documentation.
Statistical analysis. The study tested the hypothesis that
DEB were noninferior to PES in reducing in-stent
(in-balloon) late loss at follow-up angiography. The sample
size calculations were based on the assumptions that the
standard deviation of late loss was 0.5 mm in both groups,
as demonstrated in the ISAR-SMART 3 (Intracoronary
Drug-Eluting Stenting to Abrogate Restenosis in Small
Arteries) (5) and PEPCAD II (Paclitaxel-Eluting PTCA-
Balloon Catheter in Coronary Artery Disease II) (2) trials,
and that a noninferiority margin of 0.25 mm between
groups was likely to be clinically insignificant. Based on
these calculations, a sample size of 77 patients was required
in each group to show noninferiority of DEB versus PES
with an alpha error of 2.5% and a power of 80%. To account
for a 20% rate of withdrawal, lost to follow-up, or patient
refusal of follow-up angiography, a total of 182 patients
were randomized. Noninferiority for in-stent late loss was
declared if the upper limit of the 2-sided 95% confidence
interval (CI) difference in late loss (DEB minus PES) did
not exceed a delta of 0.25 mm from the observed late loss in
the PES group (12). Because noninferiority and superiority
can be assessed in the same trial without statistical penalty,
superiority testing for the primary endpoint was performed
after noninferiority was demonstrated (13,14). Superiority
of DEB over PES was declared if the upper limit of the
2-sided 95% CI for the difference in late loss did not exceed
zero.
All analyses were conducted according to the intention-
to-treat principle. Continuous variables are presented as
mean  SD and were compared by Student t test. Cate-
orical variables were compared with the chi-square or
isher exact test. A 2-sided p value 0.05 was considered
tatistically significant. All analyses were performed with the
tatistical program SAS version 9.1.3 (SAS Institute Inc.,
ary, North Carolina).
esults
total of 182 patients were enrolled at 15 Italian centers
nd randomized to treatment with DEB (n  90) in 94
lesions or PES (n  92) in 98 lesions. Baseline clinical
characteristics of the patients and treated lesions were well
matched between the 2 groups, except for a higher fre-
quency of previous percutaneous revascularization in the
DEB group (Table 1). Notably, there was a high incidence
of diabetes mellitus in both groups (43.3% in DEB and
38% in PES) and a higher incidence of insulin-treated
diabetes in the DEB group (17.8% vs. 9.8%; p  0.12).
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the major epicardial arteries, in keeping with a small-
vessel study.
Procedural characteristics are shown in Table 2. Pre-
dilation was performed almost routinely in the DEB group,
whereas direct stenting was performed in 17.3% of lesions in
the PES group. Bailout BMS was required in 20.2% of
lesions, and the stent was implanted within the DEB-
treated zone in all cases. Device success was not achieved in
all lesions treated because of the inability to adequately
pre-dilate the lesion (n  2) or impossibility to deliver the
PES (n  2) or DEB (n  1) to the lesion.
Angiographic outcomes. Baseline angiographic analyses
confirmed that lesion length, MLD, and diameter stenosis
were well matched in the 2 groups (Table 3). However, the
lesions treated in the DEB group occurred in significantly
smaller vessels than those in the PES group (2.15  0.27
mm vs. 2.26  0.24 mm; p  0.004). Based on the
quantitative coronary analyses, all lesions except for 1 in
each group had an RVD 2.8 mm as stipulated by the
inclusion criteria of the study. When subdivided by vessel
Baseline Clinical and Lesion CharacteristicsTable 1 Baseline Clinical and Lesion Characteristics
DEB PES p Value
Patients 90 92
Age, yrs 64.8 8.5 66.4 9.0 0.23
Men 72 (80) 71 (77.2) 0.64
Diabetes mellitus 39 (43.3) 35 (38) 0.47
Insulin-treated diabetes 16 (17.8) 9 (9.8) 0.12
Hypertension 72 (80) 75 (81.5) 0.79
Dyslipidemia 71 (78.9) 73 (79.3) 0.94
Current smokers 15 (16.7) 10 (10.9) 0.17
Previous MI 46 (51.1) 33 (35.9) 0.25
Previous PCI 52 (57.8) 39 (42.4) 0.04
Previous CABG 9 (10) 12 (13) 0.52
Family history of CAD 24 (26.7) 23 (25.0) 0.80
Unstable angina 22 (24.4) 20 (21.7) 0.66
Multivessel disease 56 (62.2) 56 (60.9) 0.88
Lesions 94 97
Target vessel
Left anterior descending 10 (10.6) 12 (11.5) 0.71
Diagonal 16 (17.0) 8 (8.2) 0.07
Left circumflex 10 (10.6) 16 (16.5) 0.24
Obtuse marginal/ramus 25 (26.6) 31 (32) 0.42
Right coronary artery 8 (8.5) 9 (9.3) 0.85
PDA/PL 25 (26.6) 21 (21.6) 0.42
Target lesion
Reference vessel
diameter, mm*
2.41 0.34 2.41 0.40 0.96
Lesion length, mm* 15.4 6.2 14.4 5.6 0.23
Diameter stenosis, %* 81.9 9.6 83.3 8.7 0.30
AHA type B2/C lesion 45 (47.9) 46 (47.4) 0.89
Values are mean  SD or n (%). *Visually estimated by operator.
AHA  American Heart Association; CABG  coronary artery bypass grafting; CABG  coronary
artery bypass grafting; CAD  coronary artery disease; DEB  drug-eluting balloons; MI 
myocardial infarction; PCI  percutaneous coronary intervention; PDA  posterior descending
artery; PES  paclitaxel-eluting stents; PL  posterolateral.size, the proportions of lesions in the DEB and PES group,respectively, were as follows: 2.25 mm, 64.9% versus
48.0%; 2.25 to 2.5 mm, 24.5% versus 39.8%; 2.5 to 2.8 mm,
9.6% versus 11.2%; and 2.8 mm, 1.1% versus 1.0%. Thus,
angiographic analysis confirmed that the majority of lesions
(89.4% vs. 87.8%) in the DEB and PES group occurred in
vessels with diameters2.5 mm. The acute post-procedural
result was better after stenting as compared with balloon
angioplasty with a larger final MLD, less residual stenosis,
and greater acute gain in the PES group.
Angiographic follow-up was completed in 86.2% and
83.7% (p  0.88) of lesions in the DEB and PES groups,
respectively (Fig. 1). Angiographic outcomes are displayed
in Table 4. The primary endpoint of in-stent (in-balloon) late
loss was significantly less in lesions treated with DEB compared
Baseline Procedural CharacteristicsTable 2 Baseline Procedural Characteristics
DEB (n  94) PES (n  98) p Value
Balloon pre-dilation 91 (96.8) 81 (82.7) 0.002
DEB
Diameter, mm 2.49 0.2
Length, mm 25.6 6.3
Pressure, atm 9.6 2.5
Duration of inflation, s 56.6 2.5
Bailout BMS stenting 19 (20.2)
Stent implanted within
DEB segment
19 (100)
PES
Diameter, mm 2.49 0.2
Length, mm 18.5 5.6
Pressure, atm 17.2 3.5
Post-dilation 47 (50.0)
Device success 92 (97.9) 95 (96.9) 0.69
Values are mean  SD or n (%).
BMS  bare-metal stent(s); other abbreviations as in Table 1.
Quantitative Coronary Angiography Measurementsat Baseline and After the ProcedureTable 3 Quantitative C ronary Angiography Measurementsat Baseline and After the Procedure
DEB (n  94) PES (n  97) p Value
Baseline
Reference vessel
diameter, mm
2.15 0.27 2.26 0.24 0.004
Minimal lumen
diameter, mm
0.60 0.24 0.62 0.22 0.64
Diameter stenosis, % 72.14 10.05 72.78 9.27 0.65
Length, mm 15.32 7.45 14.94 7.96 0.73
Final
Minimal lumen
diameter, mm
In-stent/in-balloon 1.56 0.32 1.99 0.28 0.001
In-segment 1.47 0.30 1.69 0.36 0.001
Diameter stenosis, %
In-stent/in-balloon 29.84 10.24 15.42 6.92 0.001
In-segment 33.21 10.56 26.84 12.54 0.001
Acute gain, mm
In-stent/in-balloon 0.96 0.30 1.37 0.31 0.001
In-segment 0.87 0.29 1.08 0.37 0.001Values are mean  SD.
Abbreviations as in Table 1.
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5% CI: 0.34 to 0.09; pnoninferiority  0.0001; psuperiority
 0.001). In-segment late loss was also less in the DEB group
(0.05  0.37 vs. 0.17  0.45 mm; difference 0.12; 95% CI:
0.25 to 0.01; pnoninferiority  0.0001; psuperiority  0.06).
Cumulative distribution curves for late loss are shown in
Figure 2. Angiographic percentage diameter stenosis at
Figure 1 Patient Flow Chart
Flow chart showing patient flow and follow-up during the study. BMS  bare-metal
Angiographic Outcomes at Follow-upTable 4 Angiographic Outcomes at Follow-up
DEB PES p Value
No. with angiographic follow-up 81 82
Minimal lumen diameter, mm
In-stent/in-balloon 1.48 0.41 1.68 0.51 0.006
In-segment 1.42 0.40 1.52 0.50 0.16
Diameter stenosis, %
In-stent/in-balloon 32.31 16.66 26.69 20.38 0.06
In-segment 34.99 15.97 33.33 19.99 0.56
Late lumen loss, mm
In-stent/in-balloon 0.08 0.38 0.29 0.44 0.001
In-segment 0.05 0.37 0.17 0.45 0.06
Net gain, mm
In-stent/in-balloon 0.87 0.41 1.06 0.52 0.009
In-segment 0.81 0.39 0.90 0.49 0.20
Binary restenosis, %
In-stent/in-balloon 8 (10) 10 (12.4) 0.64
In-segment 8 (10) 12 (14.6) 0.35Values are mean  SD or n (%).
Abbreviations as in Table 1.follow-up angiography was significantly lower in lesions
treated with PES, whereas binary in-stent and in-segment
restenosis were similar in both groups. Three of the 8 reste-
noses in the DEB group occurred in lesions treated with
bailout BMS. Based on the Mehran classification (9), the
patterns of restenosis in the DEB and PES groups were diffuse
in 3 lesions (3.7%) versus 6 lesions (7.3%), focal in 3 lesions
(3.7%) in both groups, proliferative in 1 lesion (1.2%) in both
s); DEB  drug-eluting balloon(s); PES  paclitaxel-eluting stent(s).
Figure 2 Late Loss Distribution
Cumulative frequency distribution curves of in-stent (in-balloon) late loss
at follow-up angiography.stent(
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No aneurysms were present at follow-up angiography in either
group.
Clinical outcomes. All patients, except for 1 in the PES
group, completed the 6-month follow-up. In the DEB
group, there were no cases of clinically apparent acute vessel
closure and only 1 periprocedural MI. As shown in Table 5,
the cumulative MACE rate at 6 months was 10% with DEB
and 16.3% with PES treatment in small vessels (p  0.21).
There were no statistically significant differences between
DEB and PES in the rates of death, MI, TLR, or TVR.
There were also no cases of definite or probable stent
thrombosis in the study.
Subgroup analysis. Table 6 shows the results of the sub-
group analysis with formal interaction testing, which was
performed to explore whether the reduction in the primary
endpoint of in-stent (in-balloon) late loss was consistent
Clinical OutcomesTable 5 Clinical Outcomes
DEB (n  90) PES (n  92) p Value
In-hospital MACE
Periprocedural MI 1 (1.1) 3 (3.3) 0.33
Recurrent PCI 0 0
Death 0 0
30-day MACE (days 0–30)
MACE 2 (2.2) 4 (4.3) 0.42
MI 1 (1.1) 4 (4.4) 0.18
TLR 1 (1.1) 0 0.31
TVR (including TLR) 2 (2.2) 0 0.15
Death 0 0
Cumulative MACE (days 0–180)
MACE 9 (10) 15 (16.3) 0.21
MI 1 (1.1) 5 (5.5) 0.10
TLR 4 (4.4) 7 (7.6) 0.37
TVR (including TLR) 7 (7.8) 10 (11.0) 0.46
Death 1 (1.1) 1 (1.1) 0.99
Values are n (%).
MACE  major adverse cardiac events; TLR  target lesion revascularization; TVR  target
essel revascularization; other abbreviations as in Table 1.
Subgroup Analysis of In-Stent (In-Balloon) Late LossTable 6 Subgroup Analysis of In-Stent (In-Balloon) Late Loss
No. of Lesions
DEB PES D
Diabetes
Yes 32 31 0.05
No 49 51 0.10
Reference vessel diameter
2.25 mm 54 41 0.07
2.25–2.5 mm 19 31 0.06
Lesion length
13.9 mm (median) 40 41 0.05
13.9 mm (median) 41 41 0.11
DEB only 67 82 0.02
DEB  BMS 14 82 0.37Values are mean  SD.
Abbreviations as in Tables 1 and 2.among important subgroups (of which diabetes and DEB
alone or DEB plus bailout BMS were pre-specified). The
reduction in late loss was consistent across the subgroups
tested, with no significant interactions between the random-
ized treatment and angiographic outcomes.
Discussion
The principal findings of the BELLO randomized trial
were that among patients treated for small coronary vessels,
the IN.PACT Falcon paclitaxel-coated DEB was noninfe-
rior to PES in suppressing neointimal proliferation, as
measured by angiographic late loss at 6 months. Further-
more, DEB and PES are associated with similar rates of
angiographic restenosis, MACE, and repeat revasculariza-
tion in small vessels. These results were obtained with the
need to implant BMS in 20% of patients randomized to
DEB and in a patient population including more than 40%
of patients with treated diabetes mellitus.
The reduction of angiographic in-stent (in-balloon) late
loss with DEB as compared with PES met the pre-specified
criteria not only for noninferiority but also for superiority.
Similarly, the reduction in in-segment late loss with DEB
was noninferior to that with PES. These findings confirmed
those of studies that demonstrated the efficacy of DEB in
reducing angiographic late loss after the treatment of
coronary in-stent restenosis (1,2,4) or peripheral vascular
disease (15–17). However, the validity of late loss as a
primary endpoint in a study comparing a balloon with a
stent in de novo disease may be questioned. In the seminal
trials comparing balloon angioplasty with BMS in de novo
coronary disease, balloon angioplasty was associated with a
smaller final MLD, less acute gain, and lower late loss at
follow-up (18,19). Similarly, in this study, balloon angio-
plasty was associated with a suboptimal acute angiographic
result as measured by final MLD and acute gain. Despite
these immediate results, DEB were associated with similar
angiographic restenosis and repeat revascularization rates as
compared with PES. This is probably explained by the fact
Late Loss, mm
p Value
p Value for
InteractionPES
1 0.32 0.52 0.001 0.52
6 0.28 0.39 0.06
5 0.29 0.41 0.006 0.12
1 0.37 0.49 0.02
3 0.29 0.45 0.008 0.71
2 0.30 0.43 0.03
2 0.29 0.44 0.001 —
1 0.29 0.44 0.59EB
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the very low late loss resulting in a net lumen gain, which
was comparable in both groups, particularly for the treated
segment (20,21). Furthermore, as compared with that
previously reported with an uncoated balloon in de novo
disease (18–21), the mean late loss (0.08) with DEB in this
study was very low, with more than half of the lesions
treated having a negative late loss. Finally, it should be
noted that in 2 recent randomized studies comparing DEB
versus stenting, late loss was used as a primary endpoint to
demonstrate efficacy (2) or the lack of it (22).
DEB may be particularly advantageous over DES in the
treatment of small vessels by providing an immediate and
homogenous drug uptake, avoiding inflammatory reaction
to stent struts or polymers, and respecting the normal vessel
anatomy (23,24). DEB also provide a therapeutic option in
very small vessels (2.25 mm), which comprised more than
half of the lesions treated in this study, for which DES sizes
are not available. These lesions continue to be associated
with high rates of restenosis (6,25).
There are limited data available regarding DEB in de
novo small-vessel disease, and angiographic analysis of the
treated lesions confirmed that BELLO was a true small-
vessel study with the majority of lesions having a vessel
diameter 2.5 mm, confirming its applicability to this
complex lesion subset. The only other published study,
PICCOLETO (Paclitaxel-Eluting Balloon Versus Paclitaxel-
Eluting Stent in Small Coronary Artery Diseases), was a
small single-center trial that randomized 60 patients with
small-vessel disease (2.75 mm) to the Dior paclitaxel-
coated balloon (Eurocor, Bonn, Germany) or PES. The
study was prematurely stopped before complete enrollment
because of the clear superiority of PES, which was associ-
ated with a lower rate of angiographic restenosis (10.3% vs.
32.1%; p  0.04) and MACE (13.8% vs. 35.7%; p 
0.054). Although the Dior and IN.PACT Falcon DEB are
both coated with paclitaxel at 3 g/mm2, these technologies
re not comparable and differ significantly in regards to the
alloon technology, drug-coating process, and excipient
sed as drug carrier and transport facilitator to the vessel
all. As has been demonstrated with DES platforms,
linical outcomes may be very different, despite elution of
he same drug. The only other DEB data available on
mall-vessel disease is the PEPCAD I SVD (PEPCAD to
reat Small Vessel Coronary Artery Disease) study (8). In
his prospective, nonrandomized multicenter study, 122
atients with coronary disease in small vessels (RVD 2.25 to
.8 mm) were treated with the SeQuent Please paclitaxel-
oated balloon catheter (B. Braun, Melsungen, Germany).
his study demonstrated a significantly higher late loss and
estenosis rate in lesions treated with a combination of
EB and BMS, especially if geographic mismatch oc-
urred (i.e., stent implanted in an area that was not treated
ith DEB). The investigators in the BELLO study were
articularly careful to ensure that any needed stent was
mplanted within the DEB-treated zone. As expected, weound a lower late loss when only a DEB was used
Table 6). This finding may have 2 possible explanations:
he absence of additional late loss associated with stent
mplantation or a natural selection of less complex lesions
ot requiring additional stenting. It is important to ac-
nowledge that patients treated with DEB and without
tenting did not experience any thrombotic event, acute
essel closure, or a higher rate of periprocedural MI.
In our opinion, the findings of the BELLO study should
ot be interpreted in the context of DEB as a generic
ubstitute to DES but rather as an adjunctive tool. These
ata give support to the use of DEB in circumstances in
hich the operator may not be fully confident to deploy a
ES (e.g., small vessel size, long lesions, excessive number
f DES required) because the results of DES are not as
ptimal and in an attempt to limit the amount of metal
mplanted. Additional data are necessary to support the
sage of this strategy in patients who have trouble adhering
o prolonged dual antiplatelet therapy.
tudy limitations. Because the study was powered for an
ngiographic endpoint, the sample size may be too small to
etect small differences in clinical outcomes between the 2
roups. The choice of first-generation PES rather than
econd-generation DES may also be interpreted as a limi-
ation. However, the objective in this study was to evaluate
different modalities of delivery of the same drug without
ntroducing the confounder of differing efficacy of antirest-
notic drugs.
onclusions
n this randomized trial, treatment of small-vessel disease
ith paclitaxel-coated DEB was associated with less angio-
raphic late loss and similar rates of restenosis and revascu-
arization as DES coated with the same drug. DEB appear
o be an acceptable alternative to DES in small-vessel
isease.
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